推荐产品
生物来源
human
重组
expressed in baculovirus infected insect cells
方案
≥60% (SDS-PAGE)
表单
aqueous solution
分子量
92 kDa
包装
pkg of 10 μg
制造商/商品名称
Sigma-Aldrich
浓度
>0.02 mg/mL
技术
inhibition assay: suitable
溶解性
water: soluble
NCBI登记号
UniProt登记号
应用
life science and biopharma
运输
dry ice
储存温度
−70°C
基因信息
human ... PARP2(10038)
应用
Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.
单位定义
One unit of PARP incorporates 100 pmoles of poly(ADP) in 1 minute (room temperature) from NAD into acid-insoluble form.
外形
Formulated in 25 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.05% Tween-20, 20% glycerol and 3 mM DTT.
制备说明
Thaw on ice. Upon first thaw, briefly spin tube containing enzyme to recover full content of the tube. Aliquot enzyme into single use aliquots. Store remaining undiluted enzyme in aliquots at -70°C. Note: Enzyme is very sensitive to freeze/thaw cycles.
储存分类代码
12 - Non Combustible Liquids
WGK
WGK 1
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
常规特殊物品
从最新的版本中选择一种：
PARP-2 domain requirements for DNA damage-dependent activation and localization to sites of DNA damage.
Riccio AA
Nucleic Acids Research, 44(4), 1691-1702 (2016)
PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase.
Ame JC
The Journal of Biological Chemistry, 274(25), 17860-17868 (1999)
PARP-2 regulates cell cycle-related genes through histone deacetylation and methylation independently of poly(ADP-ribosyl)ation.
Liang YC
Biochemical and Biophysical Research Communications, 431(1), 58-64 (2013)
Xiao-Nan Zhang et al.
Nature communications, 10(1), 4196-4196 (2019-09-15)
Nicotinamide adenine dinucleotide (NAD+)-dependent ADP-ribosylation plays important roles in physiology and pathophysiology. It has been challenging to study this key type of enzymatic post-translational modification in particular for protein poly-ADP-ribosylation (PARylation). Here we explore chemical and chemoenzymatic synthesis of NAD+
Sharon McGonigle et al.
Oncotarget, 6(38), 41307-41323 (2015-10-30)
Inhibition of Poly(ADP-ribose) Polymerase1 (PARP1) impairs DNA damage repair, and early generation PARP1/2 inhibitors (olaparib, niraparib, etc.) have demonstrated clinical proof of concept for cancer treatment. Here, we describe the development of the novel PARP inhibitor E7449, a potent PARP1/2
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门